Table 3. Characteristics of the Administered Treatment in Luminal Metastatic Breast Cancer With Visceral Crisis.
| Effect | Percentage | |
|---|---|---|
| Best supportive care | 12 | 34.28% |
| Chemotherapy in visceral crisis disease | 23 | 65.72% |
| First line of therapy | 23 | 65.72% |
| Treatment modality | ||
| Epirubicine and cyclophosphamide | 9 | 25% |
| Paclitaxel and bevacizumab | 7 | 20% |
| Docetaxel | 7 | 20% |
| Mode of administration IV | 23 | 65.72% |
| Number of cycle of chemotherapy infusion | ||
| One cycle | 21 | 91.30% |
| Two cycle | 2 | 8.70% |
| The mean time between visceral crisis and death | 4.7 ± 1.9 weeks |